BEIJING BEILU PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.94 CNY | +2.49% |
|
0.00% | -30.62% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,423 | 4,447 | 4,727 | 4,523 | 3,208 | 3,503 |
| Enterprise Value (EV) 1 | 3,232 | 4,199 | 4,417 | 4,204 | 3,088 | 3,545 |
| P/E ratio | 23.3 x | 12.8 x | 26.6 x | 36.7 x | 326 x | -47.5 x |
| Yield | 1.43% | 0.78% | 0.63% | 0.76% | 1.07% | - |
| Capitalization / Revenue | 5.63 x | 5.43 x | 5.71 x | 5.36 x | 4.19 x | 3.93 x |
| EV / Revenue | 5.32 x | 5.13 x | 5.34 x | 4.98 x | 4.03 x | 3.98 x |
| EV / EBITDA | 20.5 x | 20.6 x | 24.6 x | 24.2 x | 44.7 x | 150 x |
| EV / FCF | 56.3 x | 35.7 x | -1,039 x | -34.3 x | -52.9 x | -20.1 x |
| FCF Yield | 1.78% | 2.8% | -0.1% | -2.92% | -1.89% | -4.97% |
| Price to Book | 2.84 x | 3.07 x | 2.71 x | 2.44 x | 1.81 x | 2.12 x |
| Nbr of stocks (in thousands) | 488,990 | 494,690 | 494,494 | 492,718 | 491,956 | 491,935 |
| Reference price 2 | 7.000 | 8.990 | 9.560 | 9.180 | 6.520 | 7.120 |
| Announcement Date | 27/02/19 | 11/03/20 | 18/03/21 | 29/03/22 | 23/04/23 | 21/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 608.1 | 819.1 | 827.3 | 843.9 | 765.9 | 890.7 |
| EBITDA 1 | 157.8 | 203.8 | 179.7 | 173.6 | 69.09 | 23.6 |
| EBIT 1 | 140.5 | 183.2 | 137.3 | 111.4 | -5.124 | -56.82 |
| Operating Margin | 23.1% | 22.37% | 16.6% | 13.2% | -0.67% | -6.38% |
| Earnings before Tax (EBT) 1 | 164.9 | 396.8 | 173.8 | 121 | -14.76 | -101.2 |
| Net income 1 | 147.8 | 342.4 | 174.7 | 125 | 11.21 | -71.76 |
| Net margin | 24.3% | 41.81% | 21.12% | 14.81% | 1.46% | -8.06% |
| EPS 2 | 0.3000 | 0.7000 | 0.3600 | 0.2500 | 0.0200 | -0.1500 |
| Free Cash Flow 1 | 57.38 | 117.7 | -4.251 | -122.6 | -58.31 | -176.1 |
| FCF margin | 9.44% | 14.38% | -0.51% | -14.53% | -7.61% | -19.77% |
| FCF Conversion (EBITDA) | 36.35% | 57.78% | - | - | - | - |
| FCF Conversion (Net income) | 38.83% | 34.39% | - | - | - | - |
| Dividend per Share 2 | 0.1000 | 0.0700 | 0.0600 | 0.0700 | 0.0700 | - |
| Announcement Date | 27/02/19 | 11/03/20 | 18/03/21 | 29/03/22 | 23/04/23 | 21/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 42.3 |
| Net Cash position 1 | 191 | 248 | 311 | 319 | 120 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 1.792 x |
| Free Cash Flow 1 | 57.4 | 118 | -4.25 | -123 | -58.3 | -176 |
| ROE (net income / shareholders' equity) | 13% | 25.8% | 9.21% | 5.48% | -0.23% | -4.49% |
| ROA (Net income/ Total Assets) | 7.23% | 7.86% | 3.84% | 2.42% | -0.11% | -1.26% |
| Assets 1 | 2,044 | 4,355 | 4,551 | 5,160 | -10,015 | 5,696 |
| Book Value Per Share 2 | 2.470 | 2.930 | 3.520 | 3.770 | 3.610 | 3.360 |
| Cash Flow per Share 2 | 0.3900 | 0.5000 | 2.050 | 1.820 | 1.560 | 1.520 |
| Capex 1 | 54.1 | 35 | 172 | 148 | 103 | 145 |
| Capex / Sales | 8.89% | 4.27% | 20.8% | 17.51% | 13.42% | 16.24% |
| Announcement Date | 27/02/19 | 11/03/20 | 18/03/21 | 29/03/22 | 23/04/23 | 21/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -30.62% | 336M | |
| +42.83% | 750B | |
| +34.11% | 606B | |
| -5.70% | 356B | |
| +18.06% | 326B | |
| +4.63% | 286B | |
| +17.02% | 246B | |
| +9.26% | 213B | |
| -4.21% | 213B | |
| +2.43% | 167B |
- Stock Market
- Equities
- 300016 Stock
- Financials Beijing Beilu Pharmaceutical Co., Ltd